A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

In MAG-camptothecin (MAG-CPT), the topoisomerase inhibitor camptothecin is linked to a water-soluble polymer. Preclinical experiments showed enhanced antitumour efficacy and limited toxicity compared to camptothecin alone. Prior phase I trials guided the regimen used in this study. The objectives we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachters, F M, Groen, H J M, Maring, J G, Gietema, J A, Porro, M, Dumez, H, de Vries, E G E, van Oosterom, A T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409516/
https://www.ncbi.nlm.nih.gov/pubmed/15150611
http://dx.doi.org/10.1038/sj.bjc.6601811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409516/
https://www.ncbi.nlm.nih.gov/pubmed/15150611
http://dx.doi.org/10.1038/sj.bjc.6601811

Ejemplares similares